INVESTOR OVERVIEW

NASDAQ: SRTS

February 2020

SRT-100 Vision

Investor Overview

NASDAQ: SRTS

December 2020

Forward-Looking Statements

This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these

forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,”

“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,”

“potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all

forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive

dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may

or may not occur in the future or may occur on longer or shorter timelines than anticipated, including the continuation

and severity of the COVID-19 pandemic and its impact on sales and marketing. Although we believe that we have a

reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking

statements are not guarantees of future performance and that our actual results of operations, financial condition and

liquidity, and the development of the industry in which we operate may differ materially from the forward looking

statements contained in this presentation, as a result of, among others, the factors described from time to time in

Sensus Healthcare’s filings with the Securities and Exchange Commission.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in

which we operate are consistent with the forward-looking statements contained in this presentation, they may not be

predictive of results or developments in future periods. Any forward-looking statements that we make in this presentation

speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events

or circumstances after the date of this presentation. You should read carefully our “Cautionary Note Regarding Forward-

Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the

Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Safe Harbor Statement

PAGE 2

PAGE 3

▪ Large U.S. market for Superficial Radiation Therapy (SRT) with OUS and

pipeline opportunities

▪ SRT systems allow practitioners an ROI in as little as 6-9 months, with 66%

increased reimbursement for main SRT code to improve ROI (01/02/2021)

▪ Introduced Sentinel™ - a powerful I.T. platform that provides Sensus with

opportunity for shared revenue

▪ Purchased two aesthetic mobile laser companies in Florida

▪ Provides $1 million additional annual revenue and opportunity to leverage

customer base and add in proprietary lasers

▪ Proven ability to achieve profitability, with net income of $1.0 million in 4Q

2019, and expectations to resume profitability after COVID-19 pandemic

eases

▪ Strong balance sheet with $15.5 million in cash and equivalents, and no

long-term debt at Sept. 30, 2020, supported by careful attention to expenses

▪ Executive team has extensive record with capital equipment models

▪ Sculptura™ - Anisotropic Radiation Therapy (ART) with Beam

Sculpting™ capabilities / Robotic Respiratory Tracking for multiple

indications

Investment Highlights

PAGE 4

PAGE 5

PAGE 6

SRT-100+™

SRT-100 Vision™

▪ Low-energy Photon Radiotherapy

⮚ 100% of the energy is focused directly on surface

of skin using customized proprietary applicators

⮚ Penetrates no deeper than 5mm below skin’s surface

⮚ Covered by IP portfolio

▪ Scalable platform – new future indications, such

as psoriasis

▪ Sentinel multi-featured, state-of-the-art cloud

platform

Core Technology - SRT

PAGE 7

SRT-100 Vision™

PAGE 8

SRTFor Non-Melanoma Skin Cancer

(NMSC)

Mohs Surgery

PAGE 9

SRT: Superior Clinical Outcomes

PAGE 10

PAGE 11

SRT For Treatment of Keloids

▪ A keloid is an area of irregular fibrous tissue formed at the site of a scar or injury*

Treatment Challenges

▪ Surgery and other current treatment methods are not a permanent solution▪ Recurrence rates of keloids are up to 80%▪ Expensive treatments are usually paid out-of-pocket by the patient ▪ Insurance covers treatment only if combined with SRT▪ Sensus is the only FDA cleared system to treat keloids

*Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225895/Journal of Family Practice (May 2013); Keloids: Which treatment is best for your patient?

What are Keloids?

PAGE 12

SRT Keloid Outcomes

PAGE 13

Skin Cancer:

▪ Clinical multi-center study in 2019 of 776 lesions, 5 yr. retrospective study – 98.9%

cure rate

▪ Clinical study of 151 lesions on lower extremities in 2018, 97.35% cure rate and 5-year

success rate of 97%

▪ Cognetta et al (2012) retrospective analysis on 1,715 confirmed primary cutaneous

basal cell carcinoma (“BCC”) and squamous cell carcinoma (“SCC”) treated with SRT

between 2000 and 2010; 5 year recurrence rate 5%

Keloids:

▪ Clinical study in 2018 on keloid surgery followed with SRT for 297 lesions had 97%

success rate

▪ Dr. Michael Jones; Long term clinical study with 48 subjects followed over the course

of 12 months to monitor outcomes; 94% success rate

▪ Prospective study in Journal of Clinical and Aesthetic Dermatology showed Kaplan-

Meier cure rate of 85.6% from 24 months post-SRT treatment

Clinical Studies

PAGE 14

PAGE 15

Unique, image-guided therapy: “See & treat”

▪ World’s first designed to:

⮚ Track disease progression

⮚ Plan treatment

⮚ Guide therapy

⮚ Administer radiation

⮚ Evaluate treatment

⮚ Ultrasound capabilities

The SRT-100 Vision

PAGE 16

PAGE 17

Full Array of Proprietary Applicators

SLAS created by the acquisitions of Aesthetic Mobile Laser

Services and Aesthetic Laser Partners, with 30 lasers and six vans

▪ Brings to Sensus:

⮚ $1.0+ million in revenues over the next 12 months (assumes dermatology

clinics will be at 80% of their pre-COVID-19 patient levels)

⮚ Immediate earnings accretion

⮚ Full Florida coverage with150 - 200 dermatology practices

⮚ 500+ potential new customers for Sensus’ existing SRT products

⮚ Recurring revenue model via mobile laser rentals

⮚ Addition of proprietary aesthetic lasers equipped with Sentinel (FDA

clearance expected by year-end 2020

▪ Supports shared service models

▪ Permits direct patient billing

Sensus Laser Aesthetic Solutions

PAGE 19

PAGE 20

Anisotropic Radiation Therapy (ART) for Additional Indications

State-of-the-art Anisotropic Radiation Therapy device

Sculptura System

PAGE 21

⮚ Robotic respiratory motion tracking

⮚ Beam Sculpting™

⮚ Photon radiotherapy

⮚ Tomosynthesis imaging

• Ocular

• Glioblastoma

Head & Neck

• Breast

• Recurrent Breast

Breast

• Pancreatic

Pancreas

• Vaginal

• Cervical

• Ovarian

OBGYN

• Colorectal

• Stomach

• GI Tract

GI/Colorectal

• Recurrent abdomino-pelvic tumors

Pelvic

• Liver

• Bladder

Hepatobiliary

• Lung

• Thoracic

Thoracic & Lung

• Spine

• P32 plaques

CNS

• Prostate

Prostate

Pediatrics• Intra-abdominal

• Recurrent disease

Source: Dr. Neil Taunk, Penn Medicine - GLCOE

Sa

rco

ma

(soft tissu

e tru

nk

an

d e

xtre

mity

)

Sculptura Target Indications

PAGE 22

Sculptura Positioning

PAGE 23

▪ List price of $1.5 million, compared with $xxx for

competing systems

▪ Expected high-margin; consumables provide

recurring revenues

▪ Strategic rollout to university hospital centers to

support research studies for marketing use and

provide wider validation – UPENN, Rabin Medical

Center, Stanford University

▪ Established reimbursement; 8,300 potential U.S.

sites plus 8,000 international market

▪ Single, targeted dose of radiation; no need for

course of radiation treatments

⮚ Provides savings to the healthcare system

⮚ Provides better patient care; less radiation with

similar outcomes

⮚ Ease of mobility between treatment rooms

Compelling solution for Sensus, patients, physicians,

hospitals and payors

PAGE 24

Sentinel IT Solution

Features- Data and cloud storage

- Remote diagnostics

- HIPPA compliant billing

- iOS compatible

Introducing our state-of-the-art cloud platform. Sentinel is installed directly onto the SRT-100 Vision, or

Sculptura device.

▪ One-time sale of capital equipment with annual service contract

⮚ Sentinel™ software provides capability for recurring/shared revenue

programs

▪ Recurring revenue from service contracts – 34% of installed base

under service contracts

▪ Recurring revenue from SLAS

▪ Sculptura provides both one-time equipment sales revenue and

attractive recurring revenue from disposables

▪ Investing in sales and marketing

▪ Investing in direct-to-consumer programs in conjunction with

physicians,

▪ Raising awareness of SRT treatment for keloids

▪ Goal is profitability for 2021 leveraging past R&D investments

Our Financial Model

PAGE 25

▪ The lights went out as the country shut down in March 2020 to combat

COVID-19

⮚ As a result the momentum Sensus experienced in 4Q19 abruptly halted

▪ Sensus used the shutdown to keep in front of its customers, providing

PPE, and sponsoring Zoom seminars for physicians to help them navigate

the new rules for their practices

▪ SRT came to forefront in the armamentarium for non-melanoma skin

cancer, especially in the COVID-19 environment, with increased utilization

− even by Mohs surgeons

COVID-19 Impact & Reopening Plan

PAGE 26

▪ The lights are slowly and cautiously coming on now with many

states easing public health restrictions

⮚ Our sales reps are able to see new and existing customers!

▪ Following safe guidelines we expect to regain momentum with

improvement in Q4/20

▪ With increased reimbursement for SRT, we expect a resumption in

growth and sustained profitability in 2021

Management TeamJoseph C. Sardano, Founder, President & CEO

▪ Elscint Medical Imaging – Vice President driving Sales & Marketing, led to

joint acquisition between General Electric and Picker Medical (Philips)

Imaging totaling approximately $650M.

▪ GE Healthcare – GSM, Functional Imaging (Positron Emission Tomography)

imaging group, capturing #1 market share as well as reaching $320 million

in sales within the first 24 months.

▪ CTI Molecular Imaging/Siemens Medical Imaging – Sr. Vice President,

Molecular Imaging. Built top caliber team capturing 35% market share in one

year. Accelerated put-call option with Siemens resulting in an acquisition

valued at $2.2 billion.

Steve Cohen, Co-Founder and EVP of Strategic

Initiatives & Dermatology▪ Technicare (J&J) – Regional Sales Manager

▪ Don L Leasing – CEO

▪ Xoft – Regional Sales Manager

▪ Diasonics – Regional Sales Manager

Javier Rampolla, CFO▪ 20+ years of financial experience

▪ QEP – Director of Accounting

▪ Stanley Black & Decker – Asst.

controller for Latin America

Russ Price, CTO▪ 20+ years of experience in

PET/Molecular Imaging

▪ RbM Services – Product Manager

▪ Advanced Biomarker Technologies

– Contract Project Engineer

Nicolas Soro, COO

▪ Sensus Healthcare – Director of

Regulatory Affairs and Quality Assurance

▪ DemeTECH Corporation – Director of

Regulatory Affairs and Quality Assurance

▪ DemeTECH Corporation – Network

Administrator

Hoi-Bun “Benson” Suen, VP

of International Sales▪ 20+ years of bus. dev., sales &

regulatory experience

▪ Director, Bus.Dev. Fosun Pharma

▪ Sr. Mgr, Bus. Dev & Regulatory at

Chindex International

Michael Sardano, VP &

General Counsel• Sensus Healthcare – State & Federal

Regulatory Matters, Government

Affairs, & SEC Compliance

• Served on the United States Senate

Rules & Administration Committee

• Licensed State Attorney

PAGE 27

Paul Miano, VP of SLAS• Founder Aesthetic Mobile Laser

Services

• 21+ years of operational and services

experience

• Built Aesthetic Mobile Laser Services

into leader in Southeast and Southwest

Florida

✔ Disruptive patented technology adaptable to other skin

conditions and other cancers

✔ Large, growing, underserved market

✔ Significant advantage to patients compared to existing

treatments

✔ Improved physician productivity and economics

✔ Technology transitions well into the new healthcare

system: high efficacy and cost effective

✔ Sculptura™ provides an additional avenue for high-

margin growth

SRT-100 Vision™

Summary

PAGE 28

Thank You

PAGE 29